Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 27, 2018

View Archived Issues

siRNA prevents pre-eclampsia in mice and primates

Anti-Andean antibodies protect postexposure

Imiquimod analogue fights more strains of Leishmania

Lung specificity means low tox for inhalable JAK inhibitor

Presepsin is a prognostic marker in congenital heart disease

Phase I results for PIN-201104 support progression to phase II for asthma

First dosing in phase Ib study of EDP-1815 in psoriasis and atopic dermatitis

miR-21 predicts functional worsening in children with CHD-associated pulmonary hypertension

European Commission approves Poteligeo for mycosis fungoides and Sezary syndrome

FDA grants accelerated approval to Vitrakvi for advanced solid tumors with NTRK gene fusion

HBV capsid assembly inhibitors discovered at Shanghai Longwood Biopharmaceuticals

Sanford Burnham Prebys Medical Discovery Institute identifies ACP1 inhibitors

REVOLUTION Medicines synthesizes rapamycin analogues

Cyclin-dependent kinase inhibitors patented by Selection Bioscience

Gene methylation of nontumoral liver tissue predicts recurrence of HCC after surgical resection

BAT-8001, a potent anti-HER2 antibody-drug conjugate, shows promising preclinical profile

Phase I study demonstrates bioequivalence of CT-P16 with the reference bevacizumab products

Aurigene presents AU-15330, a novel dual degrader of SMARCA2/4

G1 Therapeutics reports topline data from second phase II trial of trilaciclib in first-line SCLC

Belgian clearances for phase I trial of anti-IL-7 receptor antagonist OSE-127

Janssen initiates phase I study of live biotherapeutic product VE-202 for IBD

European Commission approves pegfilgrastim biosimilar Ziextenzo

FDA clears IND for phase I trial of AVID-200 in solid tumors

Vivace Therapeutics identifies YAP1/TEAD interaction inhibitors

New BTK inhibitors developed at the Korea Research Institute of Chemical Technology

Cortexyme patents gingipain R1/R2 inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...